Why Illumina (ILMN) stock is trading up today.

{
  "signal_id": "aeac3603-a97e-4c9a-9cf0-e624bdb7eaa4",
  "signal_type": "news",
  "signal_subtype": "hires",
  "detected_at": "2026-06-24T15:35:55+00:00",
  "company": {
    "name": "Illumina",
    "domain": "illumina.com"
  },
  "data": {
    "url": "https://stockstory.org/us/stocks/nasdaq/ilmn/news/why-up-down/why-illumina-ilmn-stock-is-trading-up-today",
    "title": "Why Illumina (ILMN) stock is trading up today.",
    "contact": "Daniel M. Skovronsky",
    "excerpt": "Why Illumina (ILMN) stock is trading up today.\n\nRadek strnad /.\n\nJune 24, 2026\n\nWhat happened?\n\nShares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to its board and a price target increase from Barclays.\n\nIllumina appointed Daniel M. Skovronsky, the Chief Scientific and Product Officer of Eli Lilly, to its board of directors. The move was viewed positively, as his expertise is expected to help the company's innovation and business development efforts. Separately, Barclays analyst Luke Sergott raised the firm's price target on Illumina to $145 from $122. While the analyst kept an Underweight rating on the shares, the note mentioned that life science and diagnostic tools are \"gaining favor among healthcare subsectors,\" and the firm expects in-line to modest beats in quarterly results for the group.\n\nWhat is the market telling us.\n\nIllumina's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.\n\nThe biggest move we wrote about over the last year was 8 months ago when the stock gained 22.4% on the news that it reported third-quarter 2025 financial results that beat profit expectations and raised its...",
    "summary": "Illumina, Inc. hired Daniel M. Skovronsky as board of directors on Jun 24th '26.",
    "category": "hires",
    "found_at": "2026-06-24T15:35:55Z",
    "planning": false,
    "image_url": "https://stockstory.org/stockstory/company-image/ILMN",
    "job_title": "board of directors",
    "confidence": 0.9865,
    "assets_tags": [
      "education"
    ],
    "published_at": "2026-06-24T15:35:55Z",
    "effective_date": "2026-06-24",
    "job_title_tags": [
      "education",
      "directors"
    ],
    "article_sentence": "Illumina appointed Daniel M. Skovronsky, the Chief Scientific and Product Officer of Eli Lilly, to its board of directors."
  }
}

curl https://signals.autobound.ai/v1/signals/aeac3603-a97e-4c9a-9cf0-e624bdb7eaa4 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"illumina.com","limit":20}'